Riptide Bioscience, Inc.

9:30 AM - 9:45 AM, Tuesday, October 22, 2019 ・ 2nd Floor
Riptide is a late preclinical-stage biotechnology company developing novel peptide therapeutics for macrophage-driven cancers and fibrosis.

Riptide’s drug candidates are highly effective in syngeneic tumor models driven by a suppressive tissue microenvironment (pancreatic, prostate, breast, colon). Treatment with Riptide drug candidates transforms tumors with minimal immune cell infiltrate to tumors with elevated levels and activity by T, NK, and B cells.

- Peer-reviewed contract and grant support has been awarded by the National Cancer Institute, the Defense Department, Scleroderma Research UK, and the Rosetrees Trust.
- Highest efficacy ever demonstrated in NCI’s KRAS/p16 transgenic model of pancreatic cancer.
- Superior efficacy to chemotherapy and checkpoint inhibitor as monotherapy, and complementary as combination therapy.
- Efficacy also shown in models of macrophage-driven pulmonary fibrosis, superior to the FDA-approved drugs, perfenidone and nintedanib.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
RP832 - immunomodulatory drug candidate
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2